The class
CETi-1, AVANT Immunotherapeutics CETP-targeting vaccine, entered Phase II trials for hypercholesterolemia and atherosclerosis by 2001 (Curr Opin Investig Drugs 2004)
Original title: CETi-1. AVANT
CETi-1 is a vaccine that stimulates antibodies specific for cholesteryl ester transfer protein (CETP), developed by AVANT Immunotherapeutics for potential use in reducing atherosclerosis risk factors. Phase II trials of CETi-1 in hypercholesterolemia and atherosclerosis had been initiated by August 2001.
Original abstract
CETi-1, a vaccine that stimulates antibodies specific for cholesteryl ester transfer protein, is under development by AVANT Immunotherapeutics for potential use in reducing risk factors for atherosclerosis. Phase II trials with CETi-1 in hypercholesterolemia and atherosclerosis had been initiated by August 2001.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.